{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:37Z","timestamp":1790660197594,"version":"4.1.0"},"reference-count":226,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GINOP2.3.2-15-2016-00034","award":["TUDFO\/47138-1\/2019-ITM"],"award-info":[{"award-number":["TUDFO\/47138-1\/2019-ITM"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Neurodegeneration is one of the driving forces behind the pathogenesis of multiple sclerosis (MS). Progression without activity, pathopsychological disturbances (cognitive impairment, depression, fatigue) and even optic neuropathy seems to be mainly routed in this mechanism. In this article, we aim to give a comprehensive review of the clinical aspects and symptomology, radiological and molecular markers and potential therapeutic targets of neurodegeneration in connection with MS. As the kynurenine pathway (KP) was evidenced to play an important role in the pathogenesis of other neurodegenerative conditions (even implied to have a causative role in some of these diseases) and more and more recent evidence suggest the same central role in the neurodegenerative processes of MS as well, we pay special attention to the KP. Metabolites of the pathway are researched as biomarkers of the disease and new, promising data arising from clinical evaluations show the possible therapeutic capability of KP metabolites as neuroprotective drugs in MS. Our conclusion is that the kynurenine pathway is a highly important route of research both for diagnostic and for therapeutic values and is expected to yield concrete results for everyday medicine in the future.<\/jats:p>","DOI":"10.3390\/molecules26113423","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:59:55Z","timestamp":1623023995000},"page":"3423","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy\u2014Kynurenines Are Important Players"],"prefix":"10.3390","volume":"26","author":[{"given":"D\u00e1niel","family":"Sandi","sequence":"first","affiliation":[{"name":"Albert Szent-Gy\u00f6rgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsanett","family":"Fricska-Nagy","sequence":"additional","affiliation":[{"name":"Albert Szent-Gy\u00f6rgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Bencsik","sequence":"additional","affiliation":[{"name":"Albert Szent-Gy\u00f6rgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[{"name":"Albert Szent-Gy\u00f6rgyi Clinical Centre, Department of Neurology, Faculty of General Medicine, University of Szeged, H-6725 Szeged, Hungary"},{"name":"MTA-SZTE Neuroscience Research Group, University of Szeged, H-6725 Szeged, Hungary"},{"name":"Interdisciplinary Excellence Centre, University of Szeged, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000367614","article-title":"New multiple sclerosis phenotypic classification","volume":"72","author":"Lublin","year":"2014","journal-title":"Eur. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fneur.2017.00234","article-title":"Primary progressive multiple sclerosis: Putting together the puzzle","volume":"8","author":"Abdelhak","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: Experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1038\/s41467-018-07053-9","article-title":"Tissue-resident memory T cells populate the human brain","volume":"9","author":"Smolders","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Saji","year":"2018","journal-title":"Brain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00401-017-1744-4","article-title":"Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients","volume":"134","author":"Michels","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri1786","article-title":"Lymphoid neogenesis in chronic inflammatory diseases","volume":"6","author":"Aloisi","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0022-510X(90)90004-7","article-title":"Immunological and neuropathological significance of the Virchow-Robin space","volume":"100","author":"Esiri","year":"1990","journal-title":"J. Neurol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: Pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ana.20016","article-title":"Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion","volume":"55","author":"Barnett","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8626","DOI":"10.1523\/JNEUROSCI.3817-14.2015","article-title":"Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice","volume":"35","author":"Baxi","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1523\/JNEUROSCI.2456-15.2016","article-title":"Neurodegeneration triggers peripheral immune cell recruitment into the forebrain","volume":"36","author":"Scheld","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/brain\/awp337","article-title":"Inhibiting poly(ADP-ribose) polymerase: A potential therapy against oligodendrocyte death","volume":"133","author":"Veto","year":"2010","journal-title":"Brain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/glia.21052","article-title":"Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes","volume":"58","author":"Ziabreva","year":"2010","journal-title":"Glia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/brain\/awp046","article-title":"Mitochondrial changes within axons in multiple sclerosis","volume":"132","author":"Mahad","year":"2009","journal-title":"Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","article-title":"Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination","volume":"120","author":"Sharma","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs. relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/1352458517709619","article-title":"Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study","volume":"24","author":"Kappos","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"University of California, San Francisco MS-EPIC Team, Cree, B.A.C., Hollenbach, J.A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., and Zhu, A.H. (2019). Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol., 85, 653\u2013666.","DOI":"10.1002\/ana.25463"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"University of California, Cree, B.A., Gourraud, P.A., Oksenberg, J.R., Bevan, C., Crabtree-Hartman, E., Gelfand, J.M., Goodin, D.S., Graves, J., and Green, A.J. (2016). Long-term evolution of multiple sclerosis disability in the treatment era. Ann. Neurol., 80, 499\u2013510.","DOI":"10.1002\/ana.24747"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","article-title":"Cognitive impairment in multiple sclerosis","volume":"7","author":"Chiaravalloti","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0b013e31824528c9","article-title":"Association of MRI metrics and cognitive impairment in radiologically isolated syndromes","volume":"78","author":"Amato","year":"2012","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ana.24769","article-title":"Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom","volume":"80","author":"Cortese","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.msard.2017.06.017","article-title":"Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome","volume":"17","author":"Sandi","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1002\/brb3.875","article-title":"Progressive multiple sclerosis, cognitive function, and quality of life","volume":"8","author":"Schreiber","year":"2018","journal-title":"Brain Behav."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/WNL.41.5.685","article-title":"Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/1352458507077943","article-title":"Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis","volume":"13","author":"Glanz","year":"2007","journal-title":"Mult. Scler."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/WCO.0b013e328346a43b","article-title":"Cognition in multiple sclerosis","volume":"24","author":"Langdon","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Mult. Scler."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.msard.2015.07.006","article-title":"The Hungarian validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery and the correlation of cognitive impairment with fatigue and quality of life","volume":"4","author":"Sandi","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1177\/1352458514533229","article-title":"Characterizing cognitive function during relapse in multiple sclerosis","volume":"20","author":"Benedict","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1038\/s41598-018-26449-7","article-title":"Cognition during and after multiple sclerosis relapse as assessed with the brief international cognitive assessment for multiple sclerosis","volume":"8","author":"Giedraitiene","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1352458519898108","article-title":"Recovery of cognitive function after relapse in multiple sclerosis","volume":"27","author":"Benedict","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/bpa.12220","article-title":"Cognitive impairment in multiple sclerosis: Clinical, radiologic and pathologic insights","volume":"25","author":"DeLuca","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jnnp-2018-320050","article-title":"Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis","volume":"90","author":"Manjaly","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","article-title":"Natural history of multiple sclerosis symptoms","volume":"15","author":"Kister","year":"2013","journal-title":"Int. J. MS Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1191\/135245800678827572","article-title":"Modalities of fatigue in multiple sclerosis: Correlation with clinical and biological factors","volume":"6","author":"Iriarte","year":"2000","journal-title":"Mult. Scler."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.0b013e31827f07be","article-title":"Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy","volume":"80","author":"Kluger","year":"2013","journal-title":"Neurology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11136-010-9749-7","article-title":"Validation of the Fatigue Impact Scale in Hungarian patients with multiple sclerosis","volume":"20","author":"Losonczi","year":"2011","journal-title":"Qual. Life Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0317167100048691","article-title":"The impact of fatigue on patients with multiple sclerosis","volume":"21","author":"Fisk","year":"1994","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e01466","DOI":"10.1002\/brb3.1466","article-title":"Contributing factors to health-related quality of life in multiple sclerosis","volume":"9","author":"Biernacki","year":"2019","journal-title":"Brain Behav."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e01259","DOI":"10.1002\/brb3.1259","article-title":"Impairment and restrictions in possibly benign multiple sclerosis","volume":"9","author":"Schaefer","year":"2019","journal-title":"Brain Behav."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1590\/0004-282x20170043","article-title":"Benign multiple sclerosis: Aspects of cognition and neuroimaging","volume":"75","author":"Ton","year":"2017","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_57","unstructured":"WHO (2021, April 29). International Programme on Chemical Safety\u2014Biomarkers in Risk Assessment: Validity and Validation. Available online: http:\/\/www.inchem.org\/documents\/ehc\/ehc\/ehc222.htm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kapica-Topczewska, K., Collin, F., Tarasiuk, J., Czarnowska, A., Chorazy, M., Mironczuk, A., Kochanowicz, J., and Kulakowska, A. (2021). Assessment of disability progression independent of relapse and brain MRI activity in patients with multiple sclerosis in poland. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040868"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: Time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2019.05.010","article-title":"Lifespan normative data on rates of brain volume changes","volume":"81","author":"Battaglini","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1177\/1352458516629769","article-title":"A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients","volume":"22","author":"Zivadinov","year":"2016","journal-title":"Mult. Scler."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1177\/1352458511404916","article-title":"Grey matter volume in a large cohort of MS patients: Relation to MRI parameters and disability","volume":"17","author":"Roosendaal","year":"2011","journal-title":"Mult. Scler."},{"key":"ref_65","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"Stromillo","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.24461","article-title":"Periventricular lesions correlate with cortical thinning in multiple sclerosis","volume":"78","author":"Jehna","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.neuroimage.2006.10.006","article-title":"Focal cortical atrophy in multiple sclerosis: Relation to lesion load and disability","volume":"34","author":"Charil","year":"2007","journal-title":"Neuroimage"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamaneurol.2018.1596","article-title":"Assessing biological and methodological aspects of brain volume loss in multiple sclerosis","volume":"75","author":"Andorra","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3389\/fneur.2018.01172","article-title":"The contribution of various MRI parameters to clinical and cognitive disability in multiple sclerosis","volume":"9","author":"Toth","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.0b013e3181cbcd03","article-title":"Widespread cortical thinning characterizes patients with MS with mild cognitive impairment","volume":"74","author":"Calabrese","year":"2010","journal-title":"Neurology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1177\/1352458517692886","article-title":"Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis","volume":"23","author":"Pravata","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1352458508098373","article-title":"Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways","volume":"15","author":"Sepulcre","year":"2009","journal-title":"Mult. Scler."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.10326","article-title":"Thalamic neurodegeneration in multiple sclerosis","volume":"52","author":"Cifelli","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/01.jnen.0000190067.20935.42","article-title":"Grey matter pathology in multiple sclerosis","volume":"64","author":"Vercellino","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ana.25150","article-title":"Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease","volume":"83","author":"Azevedo","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2018.03.007","article-title":"Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: A review","volume":"22","author":"Alonso","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","article-title":"Retinal layer segmentation in multiple sclerosis: A systematic review and meta-analysis","volume":"16","author":"Petzold","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fneur.2019.00338","article-title":"Neurofilament light chain as a biomarker in multiple sclerosis","volume":"10","author":"Varhaug","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/path.1650","article-title":"The cytoskeleton in neurodegenerative diseases","volume":"204","author":"Cairns","year":"2004","journal-title":"J. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Thebault, S., Bose, G., Booth, R., and Freedman, M.S. (2021). Serum neurofilament light in MS: The first true blood-based biomarker?. Mult. Scler.","DOI":"10.1177\/1352458521993066"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1177\/1352458515574148","article-title":"Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis","volume":"21","author":"Modvig","year":"2015","journal-title":"Mult. Scler."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awy021","article-title":"Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome","volume":"141","author":"Villar","year":"2018","journal-title":"Brain"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ene.13274","article-title":"Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis","volume":"24","author":"Hakansson","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestrom","year":"2003","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1352458518782005","article-title":"Neurofilaments and 10-year follow-up in multiple sclerosis","volume":"24","author":"Bhan","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult. Scler."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Rajda, C., Galla, Z., Polyak, H., Maroti, Z., Babarczy, K., Pukoli, D., and Vecsei, L. (2020). Cerebrospinal fluid neurofilament light chain is associated with kynurenine pathway metabolite changes in multiple sclerosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082665"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458518765666","article-title":"Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis","volume":"25","author":"Siller","year":"2019","journal-title":"Mult. Scler."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"102923","DOI":"10.1016\/j.msard.2021.102923","article-title":"Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light","volume":"51","author":"Orsi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_97","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/acn3.50872","article-title":"Serum neurofilament light chain levels associations with gray matter pathology: A 5-year longitudinal study","volume":"6","author":"Jakimovski","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/ane.13078","article-title":"Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial","volume":"139","author":"Laurell","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: A critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Joisten, N., Rademacher, A., Warnke, C., Proschinger, S., Schenk, A., Walzik, D., Knoop, A., Thevis, M., Steffen, F., and Bittner, S. (2021). Exercise diminishes plasma neurofilament light chain and reroutes the kynurenine pathway in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 8.","DOI":"10.1212\/NXI.0000000000000982"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Agah, E., Zardoui, A., Saghazadeh, A., Ahmadi, M., Tafakhori, A., and Rezaei, N. (2018). Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190252"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2013.04.024","article-title":"Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity","volume":"331","author":"Szalardy","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","article-title":"The effects of natalizumab on inflammatory mediators in multiple sclerosis: Prospects for treatment-sensitive biomarkers","volume":"16","author":"Khademi","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbi.2013.08.009","article-title":"The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in natalizumab treated relapsing multiple sclerosis","volume":"35","author":"Iaffaldano","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nri912","article-title":"Emerging roles of PPARs in inflammation and immunity","volume":"2","author":"Daynes","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.4049\/jimmunol.168.5.2508","article-title":"Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis","volume":"168","author":"Diab","year":"2002","journal-title":"J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.10206","article-title":"Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis","volume":"51","author":"Feinstein","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.gene.6363832","article-title":"Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation","volume":"3","author":"Natarajan","year":"2002","journal-title":"Genes Immun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2006.05.013","article-title":"PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2","volume":"178","author":"Raikwar","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2012.12.003","article-title":"Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis","volume":"256","author":"Unoda","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1084\/jem.20082771","article-title":"The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity","volume":"206","author":"Klotz","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jneuroim.2005.06.026","article-title":"PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis","volume":"167","author":"Raikwar","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"35899","DOI":"10.1074\/jbc.M112.366419","article-title":"The peroxisome proliferator-activated receptor gamma (PPARgamma) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis","volume":"287","author":"Benedusi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"627463","DOI":"10.1155\/2008\/627463","article-title":"PPAR-gamma: Therapeutic potential for multiple sclerosis","volume":"2008","author":"Drew","year":"2008","journal-title":"PPAR Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.M414390200","article-title":"Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation","volume":"280","author":"Alonso","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.4049\/jimmunol.176.7.4385","article-title":"IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappaB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: Implication for CNS-demyelinating diseases","volume":"176","author":"Paintlia","year":"2006","journal-title":"J. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neulet.2013.08.069","article-title":"Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis","volume":"554","author":"Szalardy","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Fakan, B., Szalardy, L., and Vecsei, L. (2019). Exploiting the therapeutic potential of endogenous immunomodulatory systems in multiple sclerosis-special focus on the peroxisome proliferator-activated receptors (PPARs) and the kynurenines. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020426"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1403.003","article-title":"Genetic and hormonal regulation of tryptophan kynurenine metabolism: Implications for vascular cognitive impairment, major depressive disorder, and aging","volume":"1122","author":"Oxenkrug","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00702-010-0475-7","article-title":"Interferon-gamma-inducible kynurenines\/pteridines inflammation cascade: Implications for aging and aging-associated psychiatric and medical disorders","volume":"118","author":"Oxenkrug","year":"2011","journal-title":"J. Neural. Transm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1023\/A:1022482604276","article-title":"Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids","volume":"23","author":"Pardridge","year":"1998","journal-title":"Neurochem. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: Tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Biernacki, T., Sandi, D., Bencsik, K., and Vecsei, L. (2020). Kynurenines in the pathogenesis of multiple sclerosis: Therapeutic perspectives. Cells, 9.","DOI":"10.3390\/cells9061564"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/glia.20090","article-title":"Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons","volume":"49","author":"Guillemin","year":"2005","journal-title":"Glia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fpsyt.2015.00116","article-title":"Kynurenine 3-monooxygenase: An influential mediator of neuropathology","volume":"6","author":"Parrott","year":"2015","journal-title":"Front. Psychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj3260351","article-title":"Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types","volume":"326","author":"Heyes","year":"1997","journal-title":"Biochem. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-002-0770-z","article-title":"Kynurenate production by cultured human astrocytes","volume":"110","author":"Kiss","year":"2003","journal-title":"J. Neural. Transm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/glia.20432","article-title":"Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry","volume":"55","author":"Guidetti","year":"2007","journal-title":"Glia"},{"key":"ref_132","first-page":"716859","article-title":"The involvement of neuroinflammation and kynurenine pathway in Parkinson\u2019s disease","volume":"2011","author":"Zinger","year":"2011","journal-title":"Parkinsons Dis."},{"key":"ref_133","first-page":"309","article-title":"Neuropharmacology of quinolinic and kynurenic acids","volume":"45","author":"Stone","year":"1993","journal-title":"Pharmacol. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/13543784.2020.1813716","article-title":"Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs","volume":"29","author":"Boros","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2006.03.051","article-title":"Kynurenic acid has a dual action on AMPA receptor responses","volume":"402","author":"Prescott","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"22021","DOI":"10.1074\/jbc.M603503200","article-title":"Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00702-008-0052-5","article-title":"The Janus-face kynurenic acid","volume":"115","author":"Rozsa","year":"2008","journal-title":"J. Neural. Transm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","article-title":"On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress","volume":"33","author":"Maldonado","year":"2011","journal-title":"Neurotoxicol. Teratol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","article-title":"The kynurenine pathway and neurodegenerative disease","volume":"40","author":"Maddison","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_140","first-page":"1","article-title":"Quinolinic Acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms","volume":"5","author":"Santamaria","year":"2012","journal-title":"Int. J. Tryptophan Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/glia.10175","article-title":"Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes","volume":"41","author":"Guillemin","year":"2003","journal-title":"Glia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J."},{"key":"ref_143","first-page":"551","article-title":"Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system","volume":"226","author":"Perkins","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0197-0186(95)00091-7","article-title":"The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits","volume":"28","author":"Bochet","year":"1996","journal-title":"Neurochem. Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/nbdi.1997.0136","article-title":"Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellum","volume":"4","author":"Scherzer","year":"1997","journal-title":"Neurobiol. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(91)90134-C","article-title":"Quinolinate differentiates between forebrain and cerebellar NMDA receptors","volume":"194","author":"Monaghan","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0006-8993(83)91084-3","article-title":"Quinolinic acid: Regional variations in neuronal sensitivity","volume":"259","author":"Perkins","year":"1983","journal-title":"Brain Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","article-title":"Dysfunction of brain kynurenic acid metabolism in Huntington\u2019s disease: Focus on kynurenine aminotransferases","volume":"130","author":"Jauch","year":"1995","journal-title":"J. Neurol. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/hmg\/ddp527","article-title":"Expression analysis of novel striatal-enriched genes in Huntington disease","volume":"19","author":"Mazarei","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","article-title":"Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease","volume":"112","author":"Forrest","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington\u2019s disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Tanaka, M., Bohar, Z., and Vecsei, L. (2020). Are kynurenines accomplices or principal villains in dementia? Maintenance of kynurenine metabolism. Molecules, 25.","DOI":"10.3390\/molecules25030564"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","article-title":"Kynurenine and its metabolites in Alzheimer\u2019s disease patients","volume":"55","author":"Gulaj","year":"2010","journal-title":"Adv. Med. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1179\/174329210X12650506623645","article-title":"Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer\u2019s disease","volume":"15","author":"Bonda","year":"2010","journal-title":"Redox Rep."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Rahman, A., Ting, K., Cullen, K.M., Braidy, N., Brew, B.J., and Guillemin, G.J. (2009). The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006344"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-8993(98)00577-0","article-title":"Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain","volume":"802","author":"Rassoulpour","year":"1998","journal-title":"Brain Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"100270","DOI":"10.1016\/j.ensci.2020.100270","article-title":"Kynurenine pathway in Parkinson\u2019s disease\u2014An update","volume":"21","author":"Venkatesan","year":"2020","journal-title":"eNeurologicalSci"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870060208","article-title":"Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate","volume":"6","author":"Brotchie","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.14104","article-title":"Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia","volume":"142","author":"Havelund","year":"2017","journal-title":"J. Neurochem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"PL91","DOI":"10.1016\/0024-3205(90)90376-3","article-title":"Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism","volume":"47","author":"Graham","year":"1990","journal-title":"Life Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.07.006","article-title":"Kynurenine metabolism in plasma and in red blood cells in Parkinson\u2019s disease","volume":"239","author":"Hartai","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00417-002-0511-x","article-title":"Changes of kynurenic acid content in the rat and chicken retina during ontogeny","volume":"240","author":"Rejdak","year":"2002","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0165-3806(92)90256-V","article-title":"Developmental changes in brain kynurenic acid concentrations","volume":"68","author":"Beal","year":"1992","journal-title":"Brain Res. Dev. Brain Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1203\/00006450-200108000-00011","article-title":"Neonatal asphyxia in rats: Acute effects on cerebral kynurenine metabolism","volume":"50","author":"Schwarcz","year":"2001","journal-title":"Pediatr. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1750-3639.2002.tb00467.x","article-title":"Drug-induced apoptotic neurodegeneration in the developing brain","volume":"12","author":"Olney","year":"2002","journal-title":"Brain Pathol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/cercor\/12.11.1193","article-title":"Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death","volume":"12","author":"Csillik","year":"2002","journal-title":"Cereb. Cortex"},{"key":"ref_171","first-page":"972","article-title":"Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells","volume":"39","author":"Otori","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_172","first-page":"4313","article-title":"Ganglion cell loss after optic nerve crush mediated through AMPA-kainate and NMDA receptors","volume":"41","author":"Schuettauf","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1016\/S0042-6989(97)00047-3","article-title":"Molecular basis of glutamate toxicity in retinal ganglion cells","volume":"37","author":"Sucher","year":"1997","journal-title":"Vis. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0042-6989(02)00682-X","article-title":"Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage","volume":"43","author":"Rejdak","year":"2003","journal-title":"Vis. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.visres.2003.11.003","article-title":"Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA\/2J mice, a model of ocular hypertension","volume":"44","author":"Rejdak","year":"2004","journal-title":"Vis. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbi.2015.02.007","article-title":"Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder","volume":"46","author":"Savitz","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1038\/tp.2016.133","article-title":"An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation","volume":"6","author":"Brundin","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/7854_2016_5","article-title":"Suicidality and activation of the kynurenine pathway of tryptophan metabolism","volume":"31","author":"Bryleva","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00001756-199701200-00011","article-title":"Activated human microglia produce the excitotoxin quinolinic acid","volume":"8","author":"Espey","year":"1997","journal-title":"Neuroreport"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj2830633","article-title":"Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid","volume":"283","author":"Heyes","year":"1992","journal-title":"Biochem. J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s001090050101","article-title":"Role of macrophages\/microglia in multiple sclerosis and experimental allergic encephalomyelitis","volume":"75","author":"Benveniste","year":"1997","journal-title":"J. Mol. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(01)02017-0","article-title":"Oligodendrocyte killing by quinolinic acid in vitro","volume":"896","author":"Cammer","year":"2001","journal-title":"Brain Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1046\/j.1471-4159.1995.64031192.x","article-title":"Neurotoxin quinolinic acid is selectively elevated in spinal cords of rats with experimental allergic encephalomyelitis","volume":"64","author":"Flanagan","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/71555","article-title":"Glutamate excitotoxicity in a model of multiple sclerosis","volume":"6","author":"Pitt","year":"2000","journal-title":"Nat. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nature04301","article-title":"NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury","volume":"438","author":"Salter","year":"2005","journal-title":"Nature"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12974-014-0204-5","article-title":"Quinolinic acid toxicity on oligodendroglial cells: Relevance for multiple sclerosis and therapeutic strategies","volume":"11","author":"Sundaram","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-2094-2-16","article-title":"Quinolinic acid selectively induces apoptosis of human astrocytes: Potential role in AIDS dementia complex","volume":"2","author":"Guillemin","year":"2005","journal-title":"J. Neuroinflamm."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1471-4159.2001.00498.x","article-title":"Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection","volume":"78","author":"Guillemin","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/exnr.1998.6767","article-title":"Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task","volume":"150","author":"Shear","year":"1998","journal-title":"Exp. Neurol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/IJTR.S2318","article-title":"Effects of kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons","volume":"2","author":"Braidy","year":"2009","journal-title":"Int. J. Tryptophan Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00002030-199804000-00003","article-title":"Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex","volume":"12","author":"Kerr","year":"1998","journal-title":"AIDS"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjp.0702940","article-title":"Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: Protection by melatonin and deprenyl","volume":"128","author":"Behan","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1097\/00001756-200108280-00020","article-title":"In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum","volume":"12","author":"Santamaria","year":"2001","journal-title":"Neuroreport"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijdevneu.2005.08.004","article-title":"Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats","volume":"23","author":"Leipnitz","year":"2005","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0006-8993(99)02474-9","article-title":"Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum","volume":"858","author":"Camacho","year":"2000","journal-title":"Brain Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1046\/j.1471-4159.1997.69041629.x","article-title":"Energetic dysfunction in quinolinic acid-lesioned rat striatum","volume":"69","author":"Bordelon","year":"1997","journal-title":"J. Neurochem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1096\/fj.04-3228fje","article-title":"Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation","volume":"19","author":"Kwidzinski","year":"2005","journal-title":"FASEB J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0306-4522(00)00504-2","article-title":"Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis","volume":"102","author":"Chiarugi","year":"2001","journal-title":"Neuroscience"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12974-020-01844-y","article-title":"Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression","volume":"17","author":"Sundaram","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"41271","DOI":"10.1038\/srep41271","article-title":"Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis","volume":"7","author":"Lanz","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"e06124","DOI":"10.1016\/j.heliyon.2021.e06124","article-title":"Cuprizone markedly decreases kynurenic acid levels in the rodent brain tissue and plasma","volume":"7","author":"Polyak","year":"2021","journal-title":"Heliyon"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jnnp.42.7.640","article-title":"Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases","volume":"42","author":"Monaco","year":"1979","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4613-0381-7_30","article-title":"Serum tryptophan, kynurenine, and neopterin in patients with Guillain-Barre-syndrome (GBS) and multiple sclerosis (MS)","volume":"398","author":"Rudzite","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/00207459608986697","article-title":"Tryptophan availability and the susceptibility to stress in multiple sclerosis: A hypothesis","volume":"86","author":"Sandyk","year":"1996","journal-title":"Int. J. Neurosci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0304-3940(02)00710-3","article-title":"Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients","volume":"331","author":"Rejdak","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00702-007-0667-y","article-title":"Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis","volume":"114","author":"Rejdak","year":"2007","journal-title":"J. Neural. Transm."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrd3793","article-title":"Kynurenines in the CNS: Recent advances and new questions","volume":"12","author":"Vecsei","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awn119","article-title":"Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"131","author":"Anderson","year":"2008","journal-title":"Brain"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0404.2005.00442.x","article-title":"Kynurenine metabolism in multiple sclerosis","volume":"112","author":"Hartai","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4137\/IJTR.S4294","article-title":"Understanding the roles of the kynurenine pathway in multiple sclerosis progression","volume":"3","author":"Lim","year":"2010","journal-title":"Int. J. Tryptophan Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"41473","DOI":"10.1038\/srep41473","article-title":"Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression","volume":"7","author":"Lim","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Herman, S., Akerfeldt, T., Spjuth, O., Burman, J., and Kultima, K. (2019). Biochemical differences in cerebrospinal fluid between secondary progressive and relapsing(-)remitting multiple sclerosis. Cells, 8.","DOI":"10.3390\/cells8020084"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbi.2015.07.016","article-title":"Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms","volume":"51","author":"Aeinehband","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-398314-5.00002-7","article-title":"Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization","volume":"88","author":"Anderson","year":"2012","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1021\/jm00174a005","article-title":"4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: New antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex","volume":"33","author":"Harrison","year":"1990","journal-title":"J. Med. Chem."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Lorinczi, B., Csampai, A., Fulop, F., and Szatmari, I. (2020). Synthesis of new C-3 substituted kynurenic acid derivatives. Molecules, 25.","DOI":"10.3390\/molecules25040937"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2006.10.033","article-title":"Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists","volume":"17","author":"Borza","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3389\/fimmu.2019.01406","article-title":"The opposite effects of kynurenic acid and different kynurenic acid analogs on tumor necrosis factor-alpha (TNF-alpha) production and tumor necrosis factor-stimulated gene-6 (TSG-6) expression","volume":"10","author":"Mandi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Datki, Z., Galik-Olah, Z., Bohar, Z., Zadori, D., Fulop, F., Szatmari, I., Galik, B., Kalman, J., and Vecsei, L. (2019). Kynurenic acid and its analogs are beneficial physiologic attenuators in bdelloid rotifers. Molecules, 24.","DOI":"10.3390\/molecules24112171"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fimmu.2020.00313","article-title":"The Immunomodulator 1-methyltryptophan drives tryptophan catabolism toward the kynurenic acid branch","volume":"11","author":"Wirthgen","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Molnar, K., Lorinczi, B., Fazakas, C., Szatmari, I., Fulop, F., Kmetyko, N., Berkecz, R., Ilisz, I., Krizbai, I.A., and Wilhelm, I. (2021). SZR-104, a Novel kynurenic acid analogue with high permeability through the blood-brain barrier. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010061"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Lajko, N., Kata, D., Szabo, M., Matyas, A., Dulka, K., Foldesi, I., Fulop, F., Gulya, K., Vecsei, L., and Mihaly, A. (2020). Sensitivity of rodent microglia to kynurenines in models of epilepsy and inflammation in vivo and in vitro: Microglia activation is inhibited by kynurenic acid and the synthetic analogue SZR104. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239333"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00702-011-0755-x","article-title":"A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study: Special issue related to kynurenine","volume":"119","author":"Demeter","year":"2012","journal-title":"J. Neural. Transm."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"e00741","DOI":"10.1002\/prp2.741","article-title":"Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers","volume":"9","author":"Hansen","year":"2021","journal-title":"Pharmacol. Res. Perspect."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3423\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:09Z","timestamp":1760163069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":226,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["molecules26113423"],"URL":"https:\/\/doi.org\/10.3390\/molecules26113423","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]}}}